Hutchmed

An arrow incrementally going up stairs before pointing straight up Blue background
Biotech

Hutchmed heats up autoimmune race with phase 3 win

The phase 3 trial hit its primary endpoint, delivering a boost to an asset that was held up by quality issues in another indication.
Nick Paul Taylor Jan 7, 2026 4:39am
Paraglider over a snowy mountain

Sanofi snags CMO from BioMarin—Chutes & Ladders

Aug 29, 2025 8:30am
visual of red blood cells

Hutchmed eyes China approval for autoimmune drug after ph. 3 win

Aug 21, 2023 8:45am
pipeline

Hutchmed, NightHawk and NexImmune drop R&D programs

Nov 15, 2022 8:30am